Neurocompute scores biomedical literature, surfaces overlooked patterns, and turns Parkinson’s research into a living discovery terminal.
D grade · PMID 41897312
View analysis →D grade · PMID 42047602
View analysis →D grade · PMID 41924518
View analysis →D grade · PMID 42021324
View analysis →D grade · PMID 41959321
View analysis →D grade · PMID 42022556
View analysis →D grade · PMID 41921429
View analysis →D grade · PMID 41959530
View analysis →D grade · PMID 41990927
View analysis →D grade · PMID 42046417
View analysis →This review synthesizes evidence that skin biopsy detection of phosphorylated α-synuclein and α-synuclein seed amplification assays can identify pathological peripheral α-synuclein in prodromal synucleinopathies (notably iRBD and PAF), often before nigrostriatal degeneration, and may predict…
By highlighting a minimally invasive, scalable biomarker for early and preclinical identification and enrichment of at-risk cohorts, the work supports better patient selection and outcome measures for disease‑modifying PD trials and accelerates translational therapeutic development.
This review synthesizes recent longitudinal, neuroimaging, and lifestyle evidence to extend a conceptual framework of cognitive and motor reserve in Parkinson's disease and outlines methodological and translational directions for integrating resilience into staging and personalized interventions.
By identifying modifiable lifestyle factors, potential neuroimaging markers, and methodological pathways to quantify reserve, the paper highlights avenues for prognostic biomarker development and stratified intervention strategies that could inform therapeutic discovery, though it does not provide…
Cross-sectional study of 124 PD patients versus matched controls found similar sarcopenia prevalence but PD patients had worse balance, higher fall risk, reduced handgrip strength and appendicular muscle mass at lower percentiles, smaller calf circumference and lower fat mass despite higher protein…
Signals subtle yet clinically relevant declines in muscle mass and function in mild-to-moderate PD that can guide rehabilitation, nutritional interventions, and selection of trial endpoints for mobility/fall prevention, though it provides limited direct molecular targets for drug discovery.
The paper reports that Parkin ubiquitinates NLRP3 at K353 to drive its degradation via chaperone-mediated autophagy, suppressing PANoptosis and protecting dopaminergic neurons in rotenone cell and mouse PD models, with Parkin overexpression, CMA activation, or NLRP3 inhibition (MCC950) mitigating…
Provides an actionable, disease-relevant mechanism linking Parkin to inflammasome regulation and identifies NLRP3 inhibition and CMA activation as translatable therapeutic strategies with preclinical in vivo support for Parkinson's disease.
This study demonstrates that Parkin is essential for neuronal maturation and resilience and introduces a small-molecule Parkin agonist (FB231) that reduces α-synuclein pathology and protects dopaminergic neurons in human iPSC-derived cultures and a gut α-synuclein mouse model.
By providing a drug-like activator of Parkin with both cellular and in vivo neuroprotective effects against α-synuclein-driven pathology, the work presents a actionable, translational strategy for disease-modifying Parkinson's therapeutics.
In a 2-year longitudinal study of 28 levodopa‑naïve Parkinson's patients, women had significantly higher levodopa AUC and Cmax than men, and in women (but not men) higher exposure correlated with greater wearing‑off and dyskinesia.
Provides clinically actionable evidence that sex-specific levodopa pharmacokinetics predispose women to motor complications, supporting early plasma monitoring and sex‑adjusted dosing to reduce levodopa-related adverse effects and personalize therapy.
This human neuroimaging study reports reduced locus coeruleus neuromelanin signal in PD and subtype-specific directional effective connectivity patterns between the LC, cerebellum, and cortical regions that correlate with motor severity in tremor-dominant versus akinetic-rigid patients.
It identifies a noninvasive LC biomarker and subtype-specific functional signatures that could inform patient stratification and development of noradrenergic-targeted or personalized neuromodulation therapies in Parkinson's disease.
Introduces CLEAR, a method that aligns LLM embeddings with a disease-specific knowledge graph to improve computational drug-repurposing predictions for ADRD, including Parkinson disease–related dementia, reporting up to 30% performance gains.
Offers a scalable, context-grounded computational approach to prioritize FDA-approved repurposing candidates for Parkinson-related dementia and other ADRD in data-sparse settings, potentially accelerating translational follow-up despite lacking in vitro/in vivo validation.
In a randomized trial of 105 Parkinson's patients with constipation, adjunct Bifidobacterium animalis subsp. lactis combined with Liuwei'anxiao Capsule improved bowel movement frequency, stool form, patient-reported constipation scores and achieved a higher overall response rate versus either…
This study offers a clinically actionable, microbiome-modulating adjunct therapy for a common and quality-of-life–limiting PD nonmotor symptom, supporting the gut–brain axis as a translational target and motivating follow-up trials to assess effects on broader PD outcomes or disease progression.
In a double-blind, sham-controlled RCT of 60 Parkinson's patients (H&Y 1–3), twice-daily high-intensity tACS added to multidisciplinary intensive rehabilitation produced significantly greater and durable improvements in PDQ-39 quality-of-life scores and reductions in depression and apathy up to 24…
This trial delivers clinically actionable evidence that noninvasive high-intensity tACS can be a scalable, low-risk adjunct to rehabilitation to improve long-term QoL and non-motor symptoms in PD, making it a promising candidate for translation and for follow-up mechanistic and biomarker-driven…
In alpha‑synuclein–overexpressing SH‑SY5Y cells, incense aerosol extracts—particularly the organic phase—induce ROS‑linked mitochondrial dysfunction, programmed cell death, and a shift of alpha‑synuclein from oligomers to monomers, with limited rescue by classical antioxidants compared with…
Points to incense smoke as a distinct environmental driver of alpha‑synuclein mis‑homeostasis and mitochondrial injury, offering mechanistic targets and the rationale that PD interventions may need to address non‑canonical toxicants/mechanisms beyond general antioxidant strategies.
This review highlights MRI-guided high-intensity focused ultrasound (MRgHIFU) as a noninvasive, tract-based neuromodulation approach using patient-specific diffusion MRI and advanced sequences to directly target pathological white-matter tracts (e.g., dentatorubrothalamic in ET, pallidothalamic in…
Provides a clinically actionable, translational pathway for personalized, incisionless treatment of PD motor circuits that could expand therapeutic options and target selection (including AI-assisted planning), though it does not address molecular disease-modifying mechanisms.
In a double-blind randomized trial (STEP-PD), adding bilateral M1 intermittent theta-burst stimulation to a two-week intensive physical therapy program produced a modest but statistically significant acute improvement in OFF-state MDS-UPDRS III (Δ = -4.60, p = 0.034) with exploratory gains in gait…
Provides a readily translatable, nonpharmacologic cortical-priming approach with objective EEG biomarkers that can enhance short-term rehabilitation outcomes in PD and serve as a platform for optimizing neuromodulation parameters and studying sustained clinical effects.
Comprehensive review of natural and synthetic small molecules—including polyphenols, quinones, alkaloids, metal chelators, osmolytes, and repurposed drugs—that inhibit misfolding and aggregation of amyloid-β, tau, and α-synuclein, with medicinal chemistry and mechanistic discussion.
Valuable for Parkinson's therapeutic discovery because it compiles α‑synuclein‑targeting chemotypes and repurposing candidates and outlines mechanisms useful for hit selection and lead optimization, though it lacks deep clinical/translational validation.
A nationwide retrospective cohort study found acetylcholinesterase inhibitor (AChEI) use in Parkinson's disease dementia was associated with a 24% reduction in mortality, with larger benefits in females and in late-onset PD and no significant difference between donepezil and rivastigmine.
Provides strong clinical evidence for potential repurposing of AChEIs to improve survival in PDD and highlights sex- and age-dependent effects that warrant mechanistic and trial-focused follow-up.
TCMNet is a computational pipeline that combines LLM-guided literature mining, weighted PPI network analysis, and deep-learning binding predictions to prioritize TCM formulas and constituent compounds for Parkinson's disease, highlighting Tianma Gouteng Decoction, enhanced synergy with levodopa,…
This work offers a pragmatic, scalable triage tool to nominate herb-derived compounds, prioritized targets, and formula–drug combinations for experimental validation, accelerating translational follow-up in Parkinson's therapeutic discovery despite lacking wet-lab validation.
This randomized controlled pilot study found that adding 4 weeks of soft exoskeleton robot (SER) gait training to conventional rehabilitation significantly improved gait speed, stride length, ankle dorsiflexion, balance, and several clinical scales in people with Parkinson disease compared with…
The work provides credible, quantitative evidence that a nonpharmacologic SER intervention can produce meaningful functional gains and links improved ankle mobility to better gait—valuable for rehabilitation practice and for selecting sensitive clinical outcome measures—though it offers little…
In a small randomized, sham-controlled crossover trial of 25 mild-to-moderate PD patients, two brief sessions of left DLPFC HD-tDCS improved depressive, cognitive, and other non-motor symptom scores versus sham with good tolerability.
This study supports a safe, non-pharmacologic, symptomatic intervention for PD non-motor symptoms with translational potential for clinical management and trial design, but its small size and lack of mechanistic insight limit its value for disease-modifying therapeutic discovery.
Recently abstinent methamphetamine users showed Trail Making Test deficits consistent with Parkinsonian cognitive inflexibility, with intravenous use in women linked to greater errors.
The work highlights a clinically relevant PD-like phenotype in methamphetamine users that could inform risk stratification and tailored interventions, but offers limited mechanistic or biomarker insight for direct therapeutic discovery.
This position-statement review finds MRgFUS thalamotomy is a safe and effective, durable option for refractory essential tremor and yields significant short-term benefit for Parkinsonian tremor, though long-term durability and some adverse effects remain concerns.
Clinically important as a non‑pharmacologic, translational symptomatic therapy that informs patient management and trial design, but of limited direct value for molecular Parkinson's therapeutic discovery or disease‑modifying strategies.
